<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare the effect of sleeve gastrectomy vs medical therapy on type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and other <z:hpo ids='HP_0001513'>obesity</z:hpo>-related comorbidities (<z:hpo ids='HP_0002870'>obstructive sleep apnea</z:hpo> syndrome, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>) in prospectively enrolled and matched <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: A prospective cohort study </plain></SENT>
<SENT sid="2" pm="."><plain>Morbidly <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who either underwent sleeve gastrectomy or conventional therapy were followed up and assessed for their diabetic state and other comorbidities every 3 months for 18 months </plain></SENT>
<SENT sid="3" pm="."><plain>SETTING: Centre for the Surgical-Medical Treatment of Morbid <z:hpo ids='HP_0001513'>Obesity</z:hpo>, Policlinico "Umberto I," University of Rome "Sapienza," Italy </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS: A total of 30 morbidly <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who underwent sleeve gastrectomy (group A) and a total of 30 morbidly <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who underwent conventional therapy (group B) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In group A, the preoperative mean (SD) body mass index, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> level, and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A(1c) level were 41.3 (6.0), 166.6 (68.1) mg/dL, and 7.9% (2.1%), respectively, and, at 18 months, these values were 28.3 (5.4), 96.2 (29.4) mg/dL, and 6.0% (1.5%), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>For 80% of patients, <z:mp ids='MP_0002055'>diabetes</z:mp> was resolved </plain></SENT>
<SENT sid="7" pm="."><plain>With regard to other comorbidities, the prevalence of <z:hpo ids='HP_0002870'>obstructive sleep apnea</z:hpo> syndrome dropped from 50% to 10%, and patients reduced significantly their use of medication for <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In group B, the preoperative mean (SD) body mass index, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> level, and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A(1c) level were 39.0 (5.5), 183.7 (63.5) mg/dL, and 8.1% (1.7%), respectively, and, at 18 months, these values were 39.8 (5.0), 150 (48) mg/dL, and 7.1% (1.3%), respectively </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients remained diabetic and continued or increased their level of hypoglycemic therapy </plain></SENT>
<SENT sid="10" pm="."><plain>With regard to other comorbidities, we observed an increase in the use of medication for <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and the prevalence of <z:hpo ids='HP_0002870'>obstructive sleep apnea</z:hpo> syndrome did not change </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This study confirms the efficacy of sleeve gastrectomy in the treatment of morbidly <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic patients when compared with conventional medical treatment </plain></SENT>
</text></document>